Home Cart Sign in  
Chemical Structure| 899713-86-1 Chemical Structure| 899713-86-1

Structure of ML348
CAS No.: 899713-86-1

Chemical Structure| 899713-86-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML348 is a selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM), Exhibits 14-fold selectivity for LYPLA1 over LYPLA2, Also selective over a panel of ~30 other serine hydrolases.

Synonyms: GNF-Pf-1127; CID 3238952; SID 160654487

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML348

CAS No. :899713-86-1
Formula : C18H17ClF3N3O3
M.W : 415.79
SMILES Code : O=C(NC1=CC(C(F)(F)F)=CC=C1Cl)CN2CCN(C(C3=CC=CO3)=O)CC2
Synonyms :
GNF-Pf-1127; CID 3238952; SID 160654487
MDL No. :N/A
InChI Key :OXKNHBBDOIMFFQ-UHFFFAOYSA-N
Pubchem ID :3238952

Safety of ML348

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BRAF mutant melanoma cells <12.5 μM 72 hours ML348 did not decrease cell viability in BRAF mutant melanoma cells Oncotarget. 2016 Feb 9;7(6):7297-306
NRAS mutant melanoma cells <12.5 μM 72 hours ML348 did not decrease cell viability in NRAS mutant melanoma cells Oncotarget. 2016 Feb 9;7(6):7297-306
Human HD patient iPSC-derived cortical neurons 1 μM 7 days ML348 significantly increased the number of BDNF-containing vesicles moving in both directions and increased the linear flow. Sci Adv. 2021 Mar 31;7(14):eabb0799
STHdhQ7 and STHdhQ111 cells 10 μM 1 hour ML348 restored ER-to-Golgi to plasma membrane trafficking kinetics back to control levels in HD cells. Sci Adv. 2021 Mar 31;7(14):eabb0799

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice HdhCAG140/+ knock-in mice (CAG140) Subcutaneous injection 0.3 mg/kg/day Once daily for 28 days ML348 treatment significantly improved motor coordination and nonmotor behaviors in CAG140 mice, restored brain palmitoylation levels, and reversed neuropathology. Sci Adv. 2021 Mar 31;7(14):eabb0799
Mice 3KL αS mutant mice Intraperitoneal or oral 15 or 50 mg/kg (intraperitoneal) or 35 and 70 mg/kg (oral) Daily for 10 days (intraperitoneal) or 21 days (oral) ML348 improved motor performance and cognitive function, restored synaptic plasticity, and increased αS solubility Sci Adv. 2023 Nov 15;9(46):eadj1454

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.03mL

2.40mL

1.20mL

24.05mL

4.81mL

2.40mL

References

 

Historical Records

Categories